39 results on '"Afzali, Anita"'
Search Results
2. S847 Efficacy of Guselkumab in Patients With Moderately to Severely Active Crohn’s Disease Not in Clinical Response at Week 12: Results From the GALAXI 1 Study
3. S851 Efficacy and Safety of Guselkumab for Crohn’s Disease Through 3 Years: GALAXI-1 Long-Term Extension
4. S1027 Impact of Prior Biologic Exposure on the Durability of 3-Year Continuous Ozanimod Treatment
5. S1774 Women in GI: Empowered Women Empower Women—Impact of the Second Annual Scrubs and Heels Summit
6. S977 Health Disparities in the Care of Patients With Inflammatory Bowel Disease: A Focus on Preventive Care & the Patient Perspective
7. S852 Long-Term Clinical and Endoscopic Outcomes in True North Week 52 Clinical Remitters Over 3 Years of Treatment With Ozanimod: An Interim Analysis of the True North Open-Label Extension Study
8. S76 An Interim Analysis of 2 Years of Continuous Ozanimod Treatment From the True North Open-Label Extension Study
9. S1 Sarcopenia Is Associated With Social Determinants of Health in Patients With Inflammatory Bowel Disease
10. The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium
11. S799 Health-Related Quality of Life with Guselkumab Induction and Maintenance Therapy as Measured by PROMIS-29: Results Through Week 48 of Phase 2 GALAXI 1 Study
12. S810 Efficacy Outcomes by Symptom-Based Response Status After Induction: Week-48 Results from the GALAXI 1 Trial of Guselkumab in Crohn’s Disease
13. S731 Ozanimod Is an Effective Oral Treatment for Patients With Ulcerative Colitis Regardless of Baseline Endoscopic Disease Distribution: A Post Hoc Analysis of the Phase 3 True North Study
14. S757 Efficacy and Safety of 2 Years of Continuous Ozanimod Treatment: Interim Analysis of the True North Open-Label Extension Study
15. S2764 Racial and Ethnic Differences in Diagnosed Prevalence, Specialist Visits, and Treatment Utilization of Inflammatory Bowel Disease: Retrospective Analysis of U.S. Claims Data
16. S1493 Impostor Phenomenon and Microaggression Education and Self-Assessment in Female Healthcare Professionals in the Field of Gastroenterology
17. S938 Gender-Based Differences in Sarcopenia Screening With the SARC-F Questionnaire in Inflammatory Bowel Disease
18. S876 Efficacy of Deucravacitinib, an Oral, Selective, TYK2 Inhibitor, in Patients With Moderately to Severely Active Ulcerative Colitis and Prior Exposure to Biologic Therapy: Subanalysis From the Phase 2 LATTICE-UC Study
19. Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel
20. S931 Initial 8-week Therapy with Tofacitinib in Moderate-to-Severe Ulcerative Colitis in a Real World Prospective Multicenter Study (TOUR)
21. S748 Early PRO-2 Symptom Remission Following Guselkumab Induction Treatment: Results Through Week 12 of the Phase 2 GALAXI 1 Study
22. S749 Unmet Needs in Advanced Therapy-Naïve and Advanced Therapy-experienced Moderate-to-Severe Ulcerative Colitis Patients in the United States
23. S0668 Time to Improvement in Patient-Reported Outcomes With Tofactinib in Ulcerative Colitis: Initial Results From a Real World Prospective Multicenter Study (TOUR)
24. S0776 Inpatient Outcomes in Inflammatory Bowel Disease Patients With Non-Alcoholic Fatty Liver Disease
25. P056 Methodology and Initial Results From TOUR (Tofacitinib Response in Ulcerative Colitis): A Real World Prospective Multicenter Study
26. 718 The Experience of and Access to Rapid Infliximab Infusions at an Academic Tertiary Medical Center
27. 662 Inflammatory Bowel Disease Patients With Type 2 Diabetes and Obesity Have a Higher Annual Burden and Costs of Hospitalizations: A Call for Action
28. Inflammatory Bowel Disease: A Practical Path to Transitioning From Pediatric to Adult Care
29. Depression and Opioid Use in Patients With Inflammatory Bowel Disease Predict Higher Incidence of Emergent Encounters and Cost in the Subsequent Year: Analysis of MarketScan Claims Data
30. The Burden of 30-Day Readmission for Gastrointestinal, Pancreatic, and Liver Diseases in the United States: An Opportunity to Innovate, Strategize, and Deliver
31. Patientsʼ Perspective on Biologic Use and Route of Administration in Inflammatory Bowel Disease: A Single Center Survey Evaluation of Patient-reported Outcomes
32. Combination of Biologic Agents in the Management of Severe Refractory Crohnʼs Disease: A Case Report of Concomitant Treatment with Vedolizumab and Adalimumab
33. Challenges in Using Real-World Clinical Practice Records for Retrospective Validation of Clinical Trial Data: Lessons Learned
34. Fecal Microbiota Transplant for Treatment of Clostridium difficile Infection in Immunocompromised Patients
35. Assessment of the Safety and Efficacy of Rifaximin for the Treatment of Moderate to Severe Crohnʼs Disease: A Randomized, Prospective Crossover Study in a Single Academic Medical Center
36. Preoperative Methotrexate and Risk for Early Postoperative Complications in Inflammatory Bowel Disease: A Single-center Academic Experience
37. Fecal Microbiota Transplantation (FMT) for Treatment of Clostridium difficile Infection (CDI) in Immunocompromised Patients: ACG Governors Award for Excellence in Clinical Research
38. Assessment of the Safety and Tolerability of Oral Methotrexate in Conjunction with Biologic therapy for the Treatment of Inflammatory Bowel Disease
39. The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.